Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Articles |6 August 2002

Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes Free

Jeffrey J. Molldrem, MD; Eric Leifer, PhD; Erkut Bahceci, MD; Yogen Saunthararajah, MD; Mary Rivera, RN; Cynthia Dunbar, MD; Johnson Liu, MD; Riotoro Nakamura, MD; Neal S. Young, MD; A. John Barrett, MD

Jeffrey J. Molldrem, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Eric Leifer, PhD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Erkut Bahceci, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Yogen Saunthararajah, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Mary Rivera, RN
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Cynthia Dunbar, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Johnson Liu, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Riotoro Nakamura, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Neal S. Young, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

A. John Barrett, MD
From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

    Grant Support: Dr. Molldrem is supported, in part, by a grant from the National Institutes of Health (CA85843).

    Requests for Single Reprints: Jeffrey J. Molldrem, MD, University of Texas M.D. Anderson Cancer Center, Transplantation Immunology Section, Department of Blood and Marrow Transplantation, 1515 Holcombe Boulevard, Box 448, Houston, TX 77030; e-mail, jmolldre@mdanderson.org.

    Current Author Addresses: Dr. Molldrem: University of Texas M.D. Anderson Cancer Center, Transplantation Immunology Section, Department of Blood and Marrow Transplantation, 1515 Holcombe Boulevard, Box 448, Houston TX 77030.

    Drs. Leifer, Bahceci, Saunthararajah, Dunbar, Liu, Nakamura, Young, and Barrett and Ms. Rivera: Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10, Room 7C-103, 9000 Rockville Pike, Bethesda, MD 70892.

    Author Contributions: Conception and design: J. Molldrem, A.J. Barrett.

    Analysis and interpretation of the data: J. Molldrem, E. Leifer, E. Bahceci, Y. Saunthararajah, C. Dunbar, J. Liu, N.S. Young, A.J. Barrett.

    Drafting of the article: J. Molldrem, E. Leifer, E. Bahceci, A.J. Barrett.

    Critical revision of the article for important intellectual content: J. Molldrem, E. Leifer.

    Final approval of the article: J. Molldrem, J. Liu, A.J. Barrett.

    Provision of study materials or patients: J. Molldrem, Y. Saunthararajah, C. Dunbar, N.S. Young, R. Nakamura.

    Statistical expertise: E. Leifer, E. Bahceci.

    Administrative, technical, or logistic support: R. Nakamura.

    Collection and assembly of data: J. Molldrem, Y. Saunthararajah, M. Rivera, A.J. Barrett.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Editors’ Notes
    • Methods
    • Results
    • Discussion
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

Abstract

Background:

Almost half of the deaths that result from myelodysplastic syndromes are due to cytopenia associated with bone marrow failure. Treatment is mostly supportive care.

Objective:

To determine whether treatment with antithymocyte globulin improves cytopenia and reverses dependence on red blood cell transfusions in patients with myelodysplastic syndromes.

Design:

Single-treatment, prospective study.

Setting:

Tertiary referral center.

Patients:

61 patients with myelodysplastic syndromes.

Intervention:

Antithymocyte globulin, 40 mg/kg of body weight, given daily for 4 days.

Measurements:

Evaluation of bone marrow, blood counts, transfusions, progression, and survival for a median of 30 months (range, 1 to 88 months).

Results:

Within 8 months of treatment, 21 of 61 patients (34%) no longer required red blood cell transfusions. This independence from transfusions was maintained in 17 responders (81%) for a median of 36 months (range, 3 to 72 months). Ten of 21 patients (47.5%) with severe thrombocytopenia had sustained platelet count increases, and 6 of 11 patients (55%) with severe neutropenia had sustained neutrophil counts of greater than 1 × 109 cells/L. Characteristics favorable for response were younger patient age (P = 0.005) and lower platelet counts (P = 0.038). One of the 21 responders (5%) and 22 of the 40 nonresponders (55%) died before the end of the study (P = 0.008). One of the 21 responders (5%) and 13 of the 40 nonresponders (33%) had disease progression (P = 0.086).

Conclusions:

Although this study was a nonrandomized, single-treatment study, 34% of patients treated with antithymocyte globulin became transfusion independent. Response was associated with a statistically significant longer survival and an almost significant decreased time to disease progression. Treatment with antithymocyte globulin did not seem to be detrimental because historical overall median survival times were similar to those of nonresponders.

Editors’ Notes

Context

  • Myelodysplastic syndromes are bone marrow disorders that are characterized by ineffective hematopoiesis and leukemic transformation.

  • Almost half of the deaths caused by these syndromes are from cytopenia.

  • Standard supportive care (red blood cell and platelet transfusions and hematopoietic growth factors) often fails.

Contribution

  • This prospective case series found that one third of 61 patients with red blood cell transfusion-dependent myelodysplastic syndrome became transfusion independent within 8 months of a 4-day course of intravenous antithymocyte globulin.

Cautions

  • Before instituting treatment changes on the basis of these exciting preliminary findings, physicians should watch for controlled studies that compare transfusion and survival outcomes in patients treated with antithymocyte globulin and patients given usual care (or other therapies).

–The Editors
Myelodysplastic syndromes are clonal bone marrow disorders that usually affect older adults. An estimated 20 000 new cases are documented annually in the United States (1, 2). The incidence seems to be rising, partly because older persons represent an increasing proportion of the population and partly because of improved diagnostic ability (3). Myelodysplastic syndromes are characterized by ineffective hematopoiesis that leads to varying degrees and combinations of anemia, neutropenia, and thrombocytopenia and by a tendency to evolve to acute leukemia that is refractory to treatment. Treatment of the bone marrow failure that accompanies myelodysplastic syndromes is unsatisfactory. It relies mainly on supportive care with red blood cell and platelet transfusions, antibiotics, and combinations of hematopoietic growth factors, which may partially improve blood cell counts. Although death from myelodysplastic syndromes can occur from leukemic progression, almost half of all deaths are due to cytopenia occurring without leukemic transformation (4). Therefore, improved treatments to relieve bone marrow failure associated with myelodysplastic syndromes should be greatly beneficial in terms of survival and quality of life.
Laboratory data suggest that immune mechanisms may contribute to the cytopenia of myelodysplastic syndromes (5-7). Case reports and small studies have shown that in some patients with the hypoplastic myelodysplastic syndrome, cytopenia responds to immunosuppressive treatment with antithymocyte globulin (ATG) or cyclosporine (8-10). In a previous report, we documented the remission of dependence on red blood cell transfusions and correction of neutropenia and thrombocytopenia in 12 of 25 patients with myelodysplastic syndromes who were treated with ATG (11).
In this study, we attempted to establish the frequency of red blood cell, neutrophil, and platelet response after ATG treatment in 61 patients (including the 25 reported in our earlier study [11]) with myelodysplastic syndromes. We also wanted to determine the survival and risk for leukemia progression in patients with myelodysplastic syndromes and to identify independent risk factors for treatment response, survival, and leukemic progression.

Methods

Patients

Between January 1994 and June 1998, patients were entered into a phase II trial of ATG treatment for myelodysplastic syndromes (study 95-H-0189). Of the 71 patients who were evaluated for the study, 61 met the eligibility criteria. All patients gave written informed consent, and the Institutional Review Board of the U.S. National Heart, Lung, and Blood Institute approved the study. Patients 18 years of age or older with a diagnosis of myelodysplastic syndrome and Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less were eligible for the study. Protocol entry was restricted to patients who were dependent on red blood cell transfusions, with or without concurrent neutropenia or thrombocytopenia. Transfusion dependence was defined as having had at least three separate transfusions of two or more units of red blood cells at intervals of 2 to 4 weeks to maintain the hemoglobin level (after exclusion of blood loss as a cause of anemia). To minimize the effect of previous treatments on ATG responses, patients were required to discontinue all other treatments capable of stimulating bone marrow (that is, growth factors, cyclosporine, steroids, and androgens) at least 1 month before entering the study. Myelodysplastic syndromes were confirmed by bone marrow aspirate and biopsy and were classified according to the French–American–British criteria as refractory anemia, refractory anemia with ringed sideroblasts, or refractory anemia with excess of blasts (12). Patients with chronic myelomonocytic leukemia and those with refractory anemia and 20% or more blasts in the bone marrow in transformation to leukemia (refractory anemia with excess blast cells in transformation) were excluded. Dysplasia affecting a minimum of two hematopoietic lineages was required for diagnosis. Marrow cellularity was assessed by surveying a 1- to 2-cm core biopsy specimen taken from the posterior iliac crest. Before treatment, bone marrow cytogenetic analysis was performed for all patients. These data were used to assign a score to each patient by using the International Prognostic Scoring System (IPSS) (1). The most common reasons for excluding patients from the study were dysplasia affecting only a single lineage or a bone marrow biopsy that was inadequate to render a diagnosis.

Study Protocol

Before treatment, allergy to ATG was determined by intradermal injection of 0.1 mL of ATG at a concentration of 5 mg/mL. Antithymocyte globulin treatment was contraindicated if erythema larger than 5 mm in diameter, compared with the saline control, developed. Eligible patients were given ATG (Pharmacia, Peapack, New Jersey), 40 mg/kg of body weight daily for 4 days. Antithymocyte globulin was administered intravenously over 4 to 8 hours with oral prednisone, 1 mg/kg daily [minimum of 40 mg/d], for 10 days and then tapered by day 17. Clinic visits were scheduled at 3, 6, and 12 months and then annually. Bone marrow aspirate, biopsy specimens, and bone marrow samples for cytogenetic analysis were obtained at 6 and 12 months and then annually. Excluding transfusions and antibiotics, patients received no other treatment for myelodysplastic syndromes for at least 6 months. The main criterion for response was independence from red blood cell transfusion. This criterion was met if 1) the patient was independent from transfusion for a minimum of 6 weeks with a sustained increase in hemoglobin level, or 2) the patient maintained a stable hemoglobin level within 8 months of ATG treatment, as measured from the time the patient last received a transfusion until reinstitution of red blood cell transfusions. Standard criteria for red blood cell transfusion were followed. Transfusions were given for hemoglobin nadirs between 7 and 10 g/dL, depending on subjective tolerance of anemia in individual patients. Platelet and neutrophil counts that were the highest at 3 and 6 months of follow-up were used as the peak response. Thrombocytopenia was defined as a platelet count less than 150 × 109cells/L, and neutropenia was defined as a neutrophil count less than 1.0 × 109 cells/L. In patients with severe thrombocytopenia with a platelet count less than 20 × 109 cells/L, a response was defined as a sustained increase to at least 25 × 109 cells/L. In patients with severe neutropenia with a neutrophil count of 0.5 × 109 cells/L, a response was defined as an increase to 1.0 × 109 cells/L or greater. Morphologic characteristics of bone marrow, cellularity, and karyotype were compared before treatment, after 6 months, and then annually.

Statistical Analyses

Results were analyzed on an intention-to-treat basis. Therefore, we evaluated all patients enrolled in the study and receiving ATG, regardless of whether they completed the course of ATG. Survival was censored in December 2001, with the exception of three bone marrow transplant recipients who were censored at the time of transplantation. Survival and time to progression for the entire cohort and response duration for the responders were evaluated by using the Kaplan–Meier method (13), with pointwise confidence intervals based on the variance formula of Greenwood (14). Within-patient differences before and after ATG treatment were evaluated by using the paired t-test for continuous variables and permutation tests for categorized variables. Prognostic factors for response were assessed by using logistic regression (15). The Fisher exact test was used to compute univariate P values for categorical predictors, and the likelihood ratio chi-square test with one degree of freedom was used for continuous predictors. Cox proportional-hazards regression was used to ascertain the effects of study entry characteristics and response on survival and disease progression (16). The effect of response on survival and disease progression was analyzed by modeling response as a time-varying covariate. With this approach, when a patient is “in response,” the model assumes that the relative risk for death or disease progression differs by a fixed amount compared with a similar patient who is not “in response.” Significance in Cox analyses was determined according to the score statistic. All P values are two sided; a P value less than 0.05 was considered statistically significant. Confidence intervals, determined by using Wald methods, were used for odds ratios. Stepwise regression methods using a modified step-up algorithm were used. At each step, a score statistic criterion (P = 0.25) was used for a variable to be entered into the model and a Wald statistic criterion (P = 0.30) was used for a variable to remain in the model.

Role of the Funding Source

These studies were conducted at the U.S. National Institutes of Health and were funded by the U.S. government. No outside agency influenced our analysis or interpretation of the data or the decision to submit the data for publication. Patient care was provided by the National Institutes of Health, and all drugs used in the study were purchased at full cost by the U.S. government.

Results

Patient Characteristics

Patient characteristics are shown in Table 1. Sixty-one patients were entered into the study. The median age was 60 years, and slightly more men than women were enrolled. The median duration of disease before ATG treatment was 18 months (range, 2 to 305 months). Forty-one patients (67%) had an IPSS score of intermediate-1, and 37 patients (61%) had refractory anemia subtype. In 46% of patients, karyotypic abnormalities, primarily involving chromosomes 5, 7, and 8, were identified. Before treatment, all patients were dependent on red blood cell transfusions (median duration of transfusion dependence, 7.5 months [range, 2 to 138 months]). Forty-one patients (67%) had platelet counts less than 150 × 109 cells/L. Of these 41 patients, 21 (34%) had severe thrombocytopenia (≤ 20 × 109 cells/L). Forty-one patients (67%) had neutrophil counts of 1.5 × 109 cells/L or fewer. Of these 41, 11 (18%) had severe neutropenia (≤ 0.5 × 109 cells/L). Six patients had severe pancytopenia.

Table 1. Patient Characteristics, Diagnoses, and Treatment

Table 1. Patient Characteristics, Diagnoses, and Treatment
Sixteen patients (26%) had received no treatment other than red blood cell transfusions. Before study entry, 21 patients (36%) had received some form of immunosuppressive treatment with corticosteroids, cyclosporine, or cyclophosphamide. Thirty-seven patients (60%) had been treated with androgens or hematopoietic growth factors, and 6 patients (10%) had received B vitamins. No patients had shown any substantial hematologic responses to any of these treatments.

Outcome of Study Cohort

All 61 patients entered into the study received ATG, but only 25% to 50% of the ATG dose was given in 3 patients because of unacceptable toxicity (fivefold increase in alanine aminotransferase and aspartate aminotransferase levels in 2 patients and cardiovascular instability in 1 patient). All patients developed some degree of serum sickness (consisting of fever, rash, and arthralgia) between 7 and 14 days after treatment. No other immediate or delayed toxicity resulted from ATG treatment. Fourteen patients progressed, six to refractory anemia with excess blasts in transformation and eight to acute myelogenous leukemia. Three patients with persistent pancytopenia received an allogeneic bone marrow transplant. Thirty-eight patients were censored alive, with an actuarial survival of 64% ± 13% at a median follow-up of 44 months (range, 1 to 88 months). Twenty-three patients died, 12 from cytopenia (3 from intracranial or pulmonary hemorrhage and 9 from bacterial or fungal sepsis) and 11 following progression to refractory anemia with excess blasts in transformation or to acute myelogenous leukemia (Table 2).

Table 2. Outcome after Treatment with Antithymocyte Globulin

Table 2. Outcome after Treatment with Antithymocyte Globulin

Response to Antithymocyte Globulin

Transfusion Independence

Twenty-one of 61 patients (34%) became transfusion independent within 8 months of ATG treatment. This group was defined as ATG responders (Table 2). Median time to transfusion independence was 10 weeks; 16 patients responded within 3 months. Transfusion independence was maintained in 17 of the 21 responders (80%), and the actuarial probability of remaining transfusion independent at 5 years was 76% (95% CI, 57% to 100%). Three additional patients who did not originally respond became transfusion independent at 18, 21, and 23 months after ATG treatment. Two of these 3 patients became tranfusion independent after treatment with erythropoietin; the third received only 25% of the ATG dose. Reticulocyte counts increased in responders but not in nonresponders; peak values coincided with transfusion independence. The mean reticulocyte count increased from 49 × 109 cells/L ± 33 × 109 cells/L to 85 × 109 cells/L ± 44 × 109 cells/L in responders (P < 0.001) and from 27 × 109 cells/L ± 17 × 109 cells/L to 30 × 109 cells/L ± 30 × 109 cells/L in nonresponders (P = >0.05). Three patients became transfusion dependent after remaining transfusion independent for 1.5 to 36 months. One of these patients retained a platelet response and regained independence from red blood cell transfusion after a second course of ATG, 30 months after the first treatment.

Platelet and Neutrophil Responses

Of 21 patients with severe thrombocytopenia (platelet count ≤ 20 × 109 cells/L), 16 (12 responders and 4 nonresponders) achieved sustained (untransfused) platelet counts between 25 × 109 cells/L and 217 × 109 cells/L. The mean platelet count increased significantly from 68 × 109 cells/L to 137 × 109 cells/L (P < 0.001) in responders and from 135 × 109 cells/L to 141 × 109 cells/L (P = >0.05) in nonresponders. Of 11 patients with severe neutropenia (neutrophil count ≤ 5 × 109 cells/L), 5 of 6 responders and no nonresponders achieved sustained counts greater than or equal to 1.0 × 109 cells/L. The mean neutrophil count increased significantly from 0.91 × 109 cells/L to 1.95 × 109 cells/L (P < 0.001) in responders and from 1.72 × 109 cells/L to 1.73 × 109 cells/L (P = >0.05) in nonresponders. The number of lineages affected by cytopenia improved significantly (P < 0.001) in responders: Before treatment, all 21 responders had neutropenia with or without thrombocytopenia and were transfusion dependent. After treatment, 19 of the 21 responders had normal neutrophil and platelet counts.

Myelodysplastic Syndromes

With the exception of one responding patient who progressed to acute myelogenous leukemia, no change was seen in dysplastic features of the bone marrow aspirate at 6-month follow-up examinations. No consistent difference was seen in bone marrow cellularity at 6 months when compared with the pretreatment biopsy appearance. Cytogenetic abnormalities that were present in four of the responders persisted after treatment. One patient developed a 7q− abnormality without loss of hematopoietic response.

Factors Associated with Response to Antithymocyte Globulin

We used logistic regression models to determine the effect of pretreatment patient characteristics on the probability of response to ATG (Table 3). Neutrophil and platelet counts were transformed by taking the base 10 logarithm. In the univariate analyses, the most significant factors related to favorable response were younger patient age, myelodysplastic syndromes subtype of refractory anemia, and lower platelet counts. Contributing to a lack of response were abnormal karyotype, anemia as the only cytopenia, hypercellular marrow, older patient age, and higher platelet count. In the multivariate model, each decade of life corresponded to an odds ratio for decreasing response of 0.45 (CI, 0.27 to 0.77); a 1-log increase in platelet count had an odds ratio for response of 0.34 (CI, 0.12 to 0.92).

Table 3. Univariate and Multivariate Logistic Regression Analyses for Predicting Response

Table 3. Univariate and Multivariate Logistic Regression Analyses for Predicting Response

Factors Predicting Survival

The 5-year survival probability for the cohort of 61 patients was 64% (CI, 52% to 76%) (Figure 1, top); 23 patients (38%) died before the end of the study. In univariate analyses, the important characteristics that affected survival were age, type of myelodysplastic syndrome, neutrophil count, IPSS score, and treatment response (Table 4). However, only age, neutrophil count, and treatment response were selected by stepwise regression to be in the multivariate model (Table 4). Moreover, although IPSS score was strongly significant in the univariate analysis, its inclusion in the multivariate model did not significantly improve the model's fit (P = 0.15); the same was true for the type of myelodysplastic syndrome (P = 0.30). Figure 1 (bottom) shows the survival curves for the responders and nonresponders, with adjustment for age and neutrophil count. These curves branch at 8 months after treatment, because this is the time by which response was ascertained. Before the end of the study, only 1 of the 21 responders (5%) but 22 of the 40 nonresponders (55%) died.
Figure 1.

Overall survival of the 61 patients enrolled in the study.Top.Bottom.

Table 4. Univariate and Multivariate Cox Regression Analyses for Mortality

Table 4. Univariate and Multivariate Cox Regression Analyses for Mortality

Factors Predicting Leukemic Progression

For the 61 patients in the study, the 5-year probability of remaining progression free was 73% (CI, 61% to 85%) (Figure 2, top). Fourteen patients (22%) progressed during the study. In univariate Cox regression analyses, type of myelodysplastic syndrome, IPSS score, and treatment response were important predictors of progression (Table 5). Type of myelodysplastic syndrome, neutrophil count, and treatment response were chosen by stepwise regression to be in the multivariate model. Of these variables, only the type of myelodysplastic syndrome was significant in the multivariate model; treatment response was almost significant (Table 5). Moreover, although IPSS score was strongly significant in the univariate analysis, its inclusion in the multivariate model did not significantly improve the model's fit (P = 0.16). Figure 2 (bottom) shows the time-to-progression curves for the responders and nonresponders, with adjustment for type of myelodysplastic syndrome and neutrophil count. These curves branch at 8 months after treatment, because this is the time by which response was ascertained. Before the end of the study, only 1 of the 21 responders (5%) but 13 of the 40 nonresponders (33%) progressed.
Figure 2.

Overall time to progression (to refractory anemia with excess blast cells in transformation or to acute myelogenous leukemia) for the 61 patients enrolled in the study.Top.Bottom.

Table 5. Univariate and Multivariate Cox Regression Analyses for Leukemic Progression

Table 5. Univariate and Multivariate Cox Regression Analyses for Leukemic Progression

Discussion

We found that after ATG treatment, approximately one-third of the study patients with myelodysplastic syndromes achieved a sustained independence from red blood cell transfusion, with concomitant improvement in neutropenia and thrombocytopenia and prolonged survival without progression to leukemia. In univariate analyses, factors strongly predictive of response were younger age, refractory anemia subtype, and lower platelet counts. This analysis extends preliminary observations that ATG induced transfusion independence in some patients with myelodysplastic syndromes (8-11). Furthermore, although response was sustained in 17 of the 21 responders until end-of-study censoring, this does not take into account the possibility, seen in one of the patients who relapsed, of reestablishing transfusion independence with a second course of ATG. Three additional patients ultimately became transfusion independent after a long delay. However, these responses cannot be ascribed to ATG alone because these patients received other treatments, including erythropoietin, during follow-up.
The mechanism underlying the response to ATG is not clear. In contrast to aplastic anemia, in which marrow failure is due to an autoimmune, lymphocyte-mediated myelosuppression that is reversible by immunosuppression, marrow failure in myelodysplastic syndromes has been ascribed to ineffective hematopoiesis associated with the preleukemic state (17). However, laboratory studies suggest that immune-mediated myelosuppression also occurs in myelodysplastic syndromes. Autologous T lymphocytes from patients with myelodysplastic syndromes can suppress granulocyte and erythroid marrow cell progenitors. The suppressive activity is lost after ATG treatment (5-7). These in vitro findings and the clinical responses of myelodysplastic syndromes to immunosuppression with ATG or cyclosporine (8-11) suggest that the marrow failure in some patients with myelodysplastic syndromes is caused predominantly by an immune-mediated process similar to that described in aplastic anemia (17). Univariate analyses showed that younger patients with refractory anemia and lower platelet counts were more likely to respond. In a multivariate analysis, we found that marrow hypocellularity rather than a diagnosis of refractory anemia was an almost significant independent factor predicting response to ATG. However, the number of patients in our study is too small to confidently exclude the subtype of refractory anemia as a contributing factor for response.
Using Cox regression, we confirmed the previously reported effect of age and neutrophil count on survival and the predictive effect of neutrophil count and disease type on disease progression (1, 12). Moreover, we found that response to ATG was a strong independent variable favoring both survival and progression-free survival. The superior outcome for ATG responders was due to a low probability for leukemic progression and to the absence of cytopenia-related deaths. This was also apparent in the subset of 42 patients classified as intermediate-1 by the IPSS (1) (data not shown). Because both response and survival outcome were measured after ATG treatment, we cannot formally conclude that the response to ATG leads to prolonged survival. However, this is a likely conclusion because cytopenia improved and transfusions were no longer required in the responders.
Although our findings are of interest, they should be interpreted with caution. First, our study was not randomized, and without a control population of patients with matching prognostic criteria who received standard supportive care, it is not certain that treatment with ATG can confer an overall survival benefit in myelodysplastic syndromes. Furthermore, without a control group, the possibility that ATG may have unfavorably affected the outcome of nonresponders cannot be definitively excluded. The treatment did not appear to be detrimental, however, because the median survival of 5 months for patients with IPSS scores of either intermediate-2 or high was similar to the 6-month survival noted in the global analysis (816 patients), which was used to establish IPSS scores (1). We could not estimate the median survival of patients with either low or intermediate-1 IPSS scores because few deaths occurred in this small study; thus, no comparison could be made in these groups. Second, our study population represented a selected group of patients with myelodysplastic syndromes and severe cytopenia and anemia. The response to ATG would probably be lower in an unselected population of patients with myelodysplastic syndromes Finally, the statistical significance of response, when modeled as a time-varying covariate, is suggestive in conferring a survival benefit.
These findings raise the question of whether responders with hypoplastic bone marrow represented a subgroup of patients with a form of aplastic anemia. To avoid diagnostic confusion between myelodysplastic syndromes and aplastic anemia, we were careful to enroll into the study only patients with overt dysplasia in at least one lineage other than the erythroid series. However, accurate diagnostic separation of hypoplastic myelodysplastic syndrome from aplastic anemia is notoriously difficult and is limited by sample quality, observer differences, and the possibility of overlapping causes (18). Progenitor cell assays, which can help to determine the diagnosis in borderline cases (18), were not routinely performed in these patients. More recently, immunophenotyping using flow cytometry has been shown to help differentiate borderline cases (19). Finally, it should be noted that an assumption is made between cause and effect when ascribing delayed hematologic changes to the effect of a single 4-day course of ATG. Although it is unlikely, we cannot exclude the possibility that other treatments given before study entry could have affected the outcome.
In conclusion, these results have important implications for the management of myelodysplastic syndromes. They indicate that ATG should be further evaluated for the treatment of younger patients with myelodysplastic syndromes with refractory anemia subtype who are at risk from death from pancytopenia and in whom allogeneic stem-cell transplantation is not possible or indicated. Such patients have no curative options and have responded poorly to chemotherapy and other experimental treatments. The results also indicate that additional studies exploring different immunosuppressive regimens are warranted.

References

  1. Greenberg
    PL
    ,  
    Cox
    C
    ,  
    LeBeau
    MM
    ,  
    Fenaux
    P
    ,  
    Morel
    P
    ,  
    Sanz
    G
    ,  
    et al
    .  
    International scoring system for evaluating prognosis in myelodysplastic syndromes
    Blood
    1997
    89
    2079
    88
    PubMed
    PubMed
  2. Bennett
    JM
    .  
    Meeting highlights: therapeutic strategies and supportive care in myelodysplastic syndromes: yesterday, today and tomorrow
    Leuk Res
    1998
    22
    S1
    2
    PubMed
    CrossRef
    PubMed
  3. Williamson
    PJ
    ,  
    Kruger
    AR
    ,  
    Reynolds
    PJ
    ,  
    Hamblin
    TJ
    ,  
    Oscier
    DG
    .  
    Establishing the incidence of myelodysplastic syndrome
    Br J Haematol
    1994
    87
    743
    5
    PubMed
    CrossRef
    PubMed
  4. Mangi
    MH
    ,  
    Mufti
    GJ
    .  
    Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies
    Blood
    1992
    79
    198
    205
    PubMed
    PubMed
  5. Smith
    MA
    ,  
    Smith
    JG
    .  
    The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study
    Leuk Res
    1991
    15
    597
    601
    PubMed
    CrossRef
    PubMed
  6. Sugawara
    T
    ,  
    Endo
    K
    ,  
    Shishido
    T
    ,  
    Sato
    A
    ,  
    Kameoka
    J
    ,  
    Fukuhara
    O
    ,  
    et al
    .  
    T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes
    Am J Hematol
    1992
    41
    304
    5
    PubMed
    CrossRef
    PubMed
  7. Molldrem
    JJ
    ,  
    Jiang
    YZ
    ,  
    Stetler-Stevenson
    M
    ,  
    Mavroudis
    D
    ,  
    Hensel
    N
    ,  
    Barrett
    AJ
    .  
    Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
    Br J Haematol
    1998
    102
    1314
    22
    PubMed
    CrossRef
    PubMed
  8. Biesma
    DH
    ,  
    van den Tweel
    JG
    ,  
    Verdonck
    LF
    .  
    Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
    Cancer
    1997
    79
    1548
    51
    PubMed
    CrossRef
    PubMed
  9. Tichelli
    A
    ,  
    Gratwohl
    A
    ,  
    Wuersch
    A
    ,  
    Nissen
    C
    ,  
    Speck
    B
    .  
    Antilymphocyte globulin for myelodysplastic syndrome
    Brit J Haematol
    1988
    68
    139
    40
    PubMed
    CrossRef
  10. Jonasova
    A
    ,  
    Neuwirtova
    R
    ,  
    Cermak
    J
    ,  
    Vozobulova
    V
    ,  
    Mocikova
    K
    ,  
    Siskova
    M
    ,  
    Hochova
    I
    .  
    Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
    Br J Haematol
    1998
    100
    304
    9
    PubMed
    CrossRef
    PubMed
  11. Molldrem
    JJ
    ,  
    Caples
    M
    ,  
    Mavroudis
    D
    ,  
    Plante
    M
    ,  
    Young
    NS
    ,  
    Barrett
    AJ
    .  
    Antithymocyte globulin for patients with myelodysplastic syndrome
    Br J Haematol
    1997
    99
    699
    705
    PubMed
    CrossRef
    PubMed
  12. Bennett
    JM
    ,  
    Catovsky
    D
    ,  
    Daniel
    MT
    ,  
    Flandrin
    G
    ,  
    Galton
    DA
    ,  
    Gralnick
    HR
    ,  
    Sultan
    C
    .  
    Proposals for the classification of the myelodysplastic syndromes
    Br J Haematol
    1982
    51
    189
    99
    PubMed
    CrossRef
    PubMed
  13. Kaplan
    EL
    ,  
    Meier
    P
    .  
    Nonparametric estimation from incomplete observations
    Journal of the American Statistical Association
    1958
    53
    457
    81
    CrossRef
  14. Greenwood
    M
    .  
    A report on the natural duration of cancer. Reports on Public Health and Medical Subjects
    London
    H. M. Stationery Office
    1926
    33
    1
    26
  15. Hosmer
    D
    ,  
    Lemeshow
    S
    .  
    Applied Logistic Regression
    New York
    Wiley
    1989
  16. Cox
    DR
    .  
    Regression models and life tables
    Journal of the Royal Statistical Society
    1972
    34
    187
    220
  17. Young
    NS
    ,  
    Maciejewski
    J
    .  
    The pathophysiology of acquired aplastic anemia
    N Engl J Med
    1997
    336
    1365
    72
    PubMed
    CrossRef
    PubMed
  18. Barrett
    A
    ,  
    Saunthararajah
    Y
    ,  
    Molldrem
    J
    .  
    Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
    Semin Hematol
    2000
    37
    15
    29
    PubMed
    CrossRef
    PubMed
  19. Stetler-Stevenson
    M
    ,  
    Arthur
    DC
    ,  
    Jabbour
    N
    ,  
    Xie
    XY
    ,  
    Molldrem
    J
    ,  
    Barrett
    AJ
    ,  
    et al
    .  
    Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    Blood
    2001
    98
    979
    87
    PubMed
    CrossRef
    PubMed
Figure 1.

Overall survival of the 61 patients enrolled in the study.Top.Bottom.

Figure 2.

Overall time to progression (to refractory anemia with excess blast cells in transformation or to acute myelogenous leukemia) for the 61 patients enrolled in the study.Top.Bottom.

Table 1. Patient Characteristics, Diagnoses, and Treatment

Table 1. Patient Characteristics, Diagnoses, and Treatment

Table 2. Outcome after Treatment with Antithymocyte Globulin

Table 2. Outcome after Treatment with Antithymocyte Globulin

Table 3. Univariate and Multivariate Logistic Regression Analyses for Predicting Response

Table 3. Univariate and Multivariate Logistic Regression Analyses for Predicting Response

Table 4. Univariate and Multivariate Cox Regression Analyses for Mortality

Table 4. Univariate and Multivariate Cox Regression Analyses for Mortality

Table 5. Univariate and Multivariate Cox Regression Analyses for Leukemic Progression

Table 5. Univariate and Multivariate Cox Regression Analyses for Leukemic Progression

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Promising Therapy for Bone Marrow Failure from Myelodysplastic Syndromes

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes. Ann Intern Med. ;137:156–163. doi: 10.7326/0003-4819-137-3-200208060-00007

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2002;137(3):156-163.

DOI: 10.7326/0003-4819-137-3-200208060-00007

155 Citations

See Also

Promising Therapy for Bone Marrow Failure from Myelodysplastic Syndromes
View MoreView Less

Related Articles

Promising Therapy for Bone Marrow Failure from Myelodysplastic Syndromes
Annals of Internal Medicine; 137 (3): I-27
Acquired Aplastic Anemia
Annals of Internal Medicine; 136 (7): 534-546
Young Physician-Scientists: Internal Medicine's Challenge
Annals of Internal Medicine; 133 (10): 831-832
Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure Syndromes
Annals of Internal Medicine; 131 (6): 401-408
View MoreView Less

Journal Club

In critically ill adults, transfusion of fresh vs standard-issue red blood cells did not differ for 90-d mortality
Annals of Internal Medicine; 163 (2): JC5
A restrictive transfusion strategy reduced 45-day mortality in patients with acute upper GI bleeding
Annals of Internal Medicine; 158 (6): JC6
View MoreView Less

Related Topics

Hematology/Oncology

Hematology/Oncology.

PubMed Articles

Failing to Make Ends Meet: The Broad Clinical Spectrum of DNA Ligase IV Deficiency. Case Series and Review of the Literature.
Front Pediatr 2018;6():426.
A tumor suppressive DNA translocase named FANCM.
Crit Rev Biochem Mol Biol 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×